Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial
- 4 September 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 396 (10256), 959-967
- https://doi.org/10.1016/s0140-6736(20)31862-6
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Macrolides in critically ill patients with Middle East Respiratory SyndromeInternational Journal of Infectious Diseases, 2019
- Adjunctive therapy with azithromycin for moderate and severe acute respiratory distress syndrome: a retrospective, propensity score-matching analysis of prospectively collected data at a single centerInternational Journal of Antimicrobial Agents, 2018
- The Immunomodulatory Effects of Macrolides—A Systematic Review of the Underlying MechanismsFrontiers in Immunology, 2018
- Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) InfectionSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2017
- Clarithromycin prevents human respiratory syncytial virus-induced airway epithelial responses by modulating activation of interferon regulatory factor-3Pharmacological Research, 2016
- The Role of Macrolide Antibiotics in Increasing Cardiovascular RiskJournal of the American College of Cardiology, 2015
- Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumoniaIntensive Care Medicine, 2013
- Azithromycin and the Risk of Cardiovascular DeathNew England Journal of Medicine, 2012
- Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitisRespiratory Research, 2010
- Azithromycin Blocks Neutrophil Recruitment inPseudomonasEndobronchial InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2004